

BRAF MUTANT ONLY

**ARM1** **MEK+ BRAF** ★ standard of care

BRAFi+MEK A B C D

Demonstrate known effect of BRAF/MEKi combo as reference for other arms 
**PEP:** mPFS: ≥12mo. **SEP:** ORR: 65% **G3/4:** AE <40%

ACCEPTS ALL BRAF MUTANT PATIENTS WHO HAVE NOT ALREADY BEEN TREATED WITH BRAF INHIBITORS 
**CLASS**  
 ▪ MEK+BRAF

**ARM2** **Novel Therapeutic for BRAF Mutant Patients**

Novel BRAF targeted therapies A B C D

Investigate efficacy of new BRAF targeted treatment 
**PEP:** mPFS: ≥15mo. **SEP:** ORR: 80% **G3/4:** AE <40%

ACCEPTS BRAF MUTANT PATIENTS WHO HAVE NOT ALREADY BEEN TREATED WITH BRAF INHIBITOR 
**CLASS**  
 ▪ Next-generation pan-BRAF inhibitors  
 ▪ ERK inhibitors  
 ▪ BRAFi + MEKi + PD(L)1  
 ▪ CDK4/6 inhibitors available for combination study with BRAFi or MEKi

BRAF AGNOSTIC: ARMS BALANCED FOR BRAF MUTATIONAL STATUS AND OTHER FACTORS

**ARM3** **Physician's Choice** ★ standard of care

Physician's choice A B C D

Demonstrate the known effects of standard of care 
**PEP:** mPFS: ≥12mo. **SEP:** ORR: 55% **G3/4:** AE <60%

ACCEPTS ALL PATIENTS 
**CLASS**  
 ▪ Chemotherapy ▪ CTLA4 ▪ PD1



**ARM4** **PD1+ CTLA4** ★

PD1+CTLA4 A B C D

Demonstrate the known effects of the PD1 + CTLA4 combo 
**PEP:** mPFS: ≥12mo. **SEP:** ORR: 55% **G3/4:** AE <60%

ACCEPTS PATIENTS OF ANY MUTATIONAL STATUS WHO HAVE NOT ALREADY RECEIVED PD1+CTLA4 THERAPY 
**CLASS**  
 ▪ PD1+CTLA4

**ARM5** **PD(L)1+ Activator of Immune Response**

PD1 + Activator of Immune Response A B C D

Investigate efficacy of activators of immune response 
**PEP:** mPFS: ≥15mo. **SEP:** ORR: 55% **G3/4:** AE <60%

ACCEPTS ALL PATIENTS 
**CLASS**  
 ▪ Generate CTL response de novo  
 ▪ Oncolytic virus  
 ▪ Next-generation IL-2  
 ▪ HDACi  
 ▪ Off-the-shelf antigen vaccine  
 ▪ IL-15  
 ▪ Interferon-α

**ARM6** **PD(L)1+ Second Generation Checkpoint Inhibitor**

PD1 + Second Generation Checkpoint Inhibitor A B C D

Investigate efficacy of second generation checkpoint inhibitors 
**PEP:** mPFS: ≥15mo. **SEP:** ORR: 55% **G3/4:** AE <40%

ACCEPTS ALL PATIENTS 
**CLASS**  
 ▪ IDO inhibitors  
 ▪ CSFR1  
 ▪ OX40  
 ▪ Galectin  
 ▪ KIR  
 ▪ CEA-CAMI  
 ▪ CD27  
 ▪ GITR  
 ▪ LAG-3  
 ▪ 4-1BB  
 ▪ B7-H3

# MICAT

## TECHATLAS

A DIVISION OF RACAPITAL

NEXT STEPS FOR THERAPEUTICS

NEXT STEPS FOR PATIENTS

Treatments "graduating" from MICAT are recommended for advancement for Phase III evaluation. Each recommendation includes biomarker characterization.

New treatment arms are added.

Treatments arms that do not extend progression free survival will be halted after dosing a minimum number of patients, reducing patient and systemic burden

Biomarker signatures from all patients will be monitored and correlated with clinical endpoints and response patterns

Patients whose disease progresses will be eligible for re-randomization onto MICAT; they will have an increased chance of being allocated to a better performing treatment arm.

LEGEND		
	Patient Group	<b>PEP</b> Primary endpoint
	Treatment	<b>SEP</b> Secondary endpoint
	Purpose	<b>mPFS</b> median progression free survival
	Entry criteria for therapeutic	<b>G3/4 AE</b> Grade 3/4 adverse event
		<b>ORR</b> Overall response rate

  

MUTATIONAL STATUS					
BRAF WT			BRAF mutant		
PATIENT GROUP	TARGET	NAME OF DRUG	PATIENT GROUP	TARGET	NAME OF DRUG
A	PD1	pembrolizumab	C	PD1	pembrolizumab
		nivolumab			nivolumab
B	PD1+CTLA4	nivolumab + ipilimumab	D	PD1+CTLA4	nivolumab + ipilimumab